These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma. Winner M; Goff SL; Chabot JA Semin Oncol; 2015 Feb; 42(1):86-97. PubMed ID: 25726054 [TBL] [Abstract][Full Text] [Related]
4. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis. Wang H; Zhao Q Ann Diagn Pathol; 2012 Oct; 16(5):427. PubMed ID: 22561135 [No Abstract] [Full Text] [Related]
5. A review of response in neoadjuvant therapy for exocrine pancreatic cancer. Vitello DJ; Bentrem DJ J Surg Oncol; 2021 May; 123(6):1449-1459. PubMed ID: 33831249 [TBL] [Abstract][Full Text] [Related]
6. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma means no residual tumor: no need to assess "viability". Krasinskas AM Ann Diagn Pathol; 2012 Apr; 16(2):158-9. PubMed ID: 22405469 [No Abstract] [Full Text] [Related]
7. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. Álvarez R; Alés I; Díaz R; de Paredes BG; Hidalgo M Clin Transl Oncol; 2017 Oct; 19(10):1193-1198. PubMed ID: 28612203 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research. Cloyd JM; Tsung A; Hays J; Wills CE; Bridges JF World J Gastroenterol; 2020 Jan; 26(4):375-382. PubMed ID: 32063686 [TBL] [Abstract][Full Text] [Related]
11. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998 [TBL] [Abstract][Full Text] [Related]
12. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection. Ren W; Xourafas D; Ashley SW; Clancy TE J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122 [TBL] [Abstract][Full Text] [Related]
14. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma. Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665 [TBL] [Abstract][Full Text] [Related]
15. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. Kang CM; Hwang HK; Choi SH; Lee WJ Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243 [TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Chawla A; Molina G; Pak LM; Rosenthal M; Mancias JD; Clancy TE; Wolpin BM; Wang J Ann Surg Oncol; 2020 Apr; 27(4):1191-1200. PubMed ID: 31802297 [TBL] [Abstract][Full Text] [Related]
17. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection. Boone BA; Zenati MS; Rieser C; Hamad A; Al-Abbas A; Zureikat AH; Hogg ME; Neal MD; Zeh HJ Ann Surg Oncol; 2019 May; 26(5):1503-1511. PubMed ID: 30652227 [TBL] [Abstract][Full Text] [Related]
18. Nodal downstaging as a treatment goal for node-positive pancreatic cancer. Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009 [TBL] [Abstract][Full Text] [Related]
19. More Explorations Needed to Assess Matrix Metalloproteinase 7 Expression When Predicting the Pathologic Response to Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Wang L; Niu W JAMA Surg; 2023 Jan; 158(1):102-103. PubMed ID: 36223123 [No Abstract] [Full Text] [Related]
20. Neoadjuvant therapy versus upfront resection for clinically "resectable" pancreatic cancer: The debate continues. Sarr MG; Behrns KE Surgery; 2020 Dec; 168(6):993. PubMed ID: 33066983 [No Abstract] [Full Text] [Related] [Next] [New Search]